Investigations into inhibitor type and mode, simulated gastrointestinal digestion, and cell transport of the angiotensin I-Converting enzyme-inhibitory peptides in pacific hake (Merluccius productus) fillet hydrolysate

被引:87
作者
Cinq-Mars, Crystal D. [1 ]
Hu, Chun [1 ]
Kitts, David D. [1 ]
Li-Chan, Eunice C. Y. [1 ]
机构
[1] Univ British Columbia, Fac Land & Food Syst, Food Nutr & Hlth Program, Vancouver, BC V6T 1Z4, Canada
关键词
ACE-inhibitory activity; fish protein hydrolysate; Pacific hake; simulated gastrointestinal digestion; inhibitor type; inhibitor mode; Caco-2 cell transport assay; MALDI-ToF;
D O I
10.1021/jf072277p
中图分类号
S [农业科学];
学科分类号
09 [农学];
摘要
Fish protein hydrolysate (FPH) produced by incubation of Pacific hake fillet with 3.00% Protamex at pH 6.5 and 40 degrees C for 125 min demonstrated in vitro ACE-inhibitory activity (IC50 = 165,mu g/mL), which was enhanced by ultrafiltration through a 10 kDa molecular weight cutoff membrane (IC50 = 44 mu g/mL). However, after simulated gastrointestinal digestion, FPH and ultrafiltrate had similar ACE-inhibitory activity (IC50 = 90 mu g/mL), indicating that FPH peptides act as "pro-drug type" inhibitors and that enrichment by ultrafiltration may be unnecessary. Matrix-assisted laser desorption/ionization-time of flight mass spectrometry confirmed that the molecular weights of major peaks were < 1 kDa regardless of ultrafiltration. ACE-inhibitory activities of digested hydrolysates were not significantly affected by preincubation with ACE (P > 0.05) and exhibited a competitive inhibitory mode. A permeability,assay using fully differentiated colorectal adenocarcinoma (Caco-2) cells showed an apical to basolateral transport of peptides that ranged from similar to 2 to 20% after 2 h at 37 degrees C. Pacific hake fillet hydrolysates are a potentially bioavailable source of ACE-inhibitory peptides awaiting further in vivo study.
引用
收藏
页码:410 / 419
页数:10
相关论文
共 33 条
[1]
Caco-2 monolayers in experimental and theoretical predictions of drug transport (Reprinted from Advanced Drug Delivery Reviews, vol 22, pg 67-84, 1996) [J].
Artursson, P ;
Palm, K ;
Luthman, K .
ADVANCED DRUG DELIVERY REVIEWS, 2001, 46 (1-3) :27-43
[2]
The use of the intestinal epithelial cell culture model, Caco-2, in pharmaceutical development [J].
Bailey, CA ;
Bryla, P ;
Malick, AW .
ADVANCED DRUG DELIVERY REVIEWS, 1996, 22 (1-2) :85-103
[3]
The ABCs of drug transport in intestine and liver: efflux proteins limiting drug absorption and bioavailability [J].
Chan, LMS ;
Lowes, S ;
Hirst, BH .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2004, 21 (01) :25-51
[4]
Optimizing angiotensin I-Converting enzyme inhibitory activity of pacific hake (Merluccius productus) fillet hydrolysate using response surface methodology and ultrafiltration [J].
Cinq-Mars, Crystal D. ;
Li-Chan, Eunice C. Y. .
JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 2007, 55 (23) :9380-9388
[5]
SPECTROPHOTOMETRIC ASSAY AND PROPERTIES OF ANGIOTENSIN-CONVERTING ENZYME OF RABBIT LUNG [J].
CUSHMAN, DW ;
CHEUNG, HS .
BIOCHEMICAL PHARMACOLOGY, 1971, 20 (07) :1637-+
[6]
LKPNM: a prodrug-type ACE-inhibitory peptide derived from fish protein [J].
Fujita, H ;
Yoshikawa, M .
IMMUNOPHARMACOLOGY, 1999, 44 (1-2) :123-127
[7]
Fujita H, 2000, J FOOD SCI, V65, P564, DOI 10.1111/j.1365-2621.2000.tb16049.x
[8]
FUJITA H, 1995, CLIN EXPT PHARM PH S, V1, pS304
[9]
Production kinetics of angiotensin-I converting enzyme inhibitory peptides from bonito meat in artificial gastric juice [J].
Hasan, F ;
Kitagawa, M ;
Kumada, Y ;
Hashimoto, N ;
Shiiba, M ;
Katoh, S ;
Terashima, M .
PROCESS BIOCHEMISTRY, 2006, 41 (03) :505-511
[10]
Hernández-Ledesma B, 2004, INT DAIRY J, V14, P889, DOI [10.1016/j.idairyj.2004.02.011, 10.1016/j.dairyj.2004.02.011]